At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 71 enrolled
Drug / intervention
Necitumumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating Necitumumab and Pembrolizumab for Stage IV Non-Small Cell Lung Cancer. Completed, enrolled 71 participants across 16 sites in 4 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Non-Small Cell Lung Cancer
CountriesFrance, Japan, Spain, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartSep 2015
Primary CompletionJan 2017
Study CompletionSep 2019
TodayJul 2026
First PostedMay 22, 2015
Enrollment StartSep 4, 2015
Primary CompletionJan 26, 2017
Study CompletionSep 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.1 years ago
Interventions
Necitumumabdrug
Administered IV
Pembrolizumabdrug
Administered IV